Shaolin Paul

Chief Financial Officer at Sarah Cannon Research Institute

Shaolin Paul has a diverse work experience spanning multiple industries. Shaolin started their career as an Assistant Management Accountant at ECI Human Capital in 2002. From there, they worked as an Accountant at Bradford & Bingley before moving on to the London Borough of Barnet as a Senior Management Accountant. In 2007, they became the Finance Manager at London Care, a leading provider of care services. In 2009, they joined City & County Healthcare Group as a Financial Controller. In 2015, Shaolin became the Interim Director of Finance Operations at HCA International Ltd. Shaolin then became the Chief Financial Officer at Leaders in Oncology Care in 2014. Shaolin's career progressed within the healthcare industry as they took on the role of Chief Financial Officer at Sarah Cannon Research Institute in 2018. Currently, Shaolin holds the position of Chief Financial Officer of the Cancer Department, Joint Ventures, and Sarah Cannon UK at HCA Healthcare UK, which they started in 2019.

Shaolin Paul began their education in 2002 at the AAT, where they pursued a degree in accounting from 2002 to 2003. Shaolin then furthered their studies at CIMA from 2004 to 2007, earning a degree in management accounting. Recently, in 2023, Shaolin enrolled at Bayes Business School to pursue a Global MBA.

Location

London, United Kingdom

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.


Employees

501-1,000

Links